echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zai Lab's Omacycline is approved and Hisun Pharmaceutical has the right to promote in China soon

    Zai Lab's Omacycline is approved and Hisun Pharmaceutical has the right to promote in China soon

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Zai Lab Class 1 new drugs "ZL-2401 p-toluenesulfonate tablets" and "ZL-2401 p-toluenesulfonate tablets for injection" (relevant acceptance numbers are CXHS2000002 and CXHS2000003 respectively) have entered the administrative approval stage.


    ZL-2401 p-toluenesulfonate (Omadacycline, omacycline tosylate) is a new type of 9-aminomethylcycline drug, after chemical group modification based on the tetracycline antibiotic minocycline The resulting semi-synthetic compound has broad-spectrum antibacterial activity.


    Omadacycline was developed by Paratek Pharmaceuticals


    The research results of the in vitro antibacterial activity of omacycline by the broth microdilution method by the Institute of Antibiotics of Huashan Hospital showed that: (1) omacycline is the most common pathogen of ABSSSI and CABP, such as Staphylococcus aureus and Streptococcus pyogenes , Streptococcus pneumoniae and Haemophilus influenzae have shown strong in vitro inhibitory activity; (2) Omacycline has a significant antibacterial effect on common drug-resistant strains: Methicillin-resistant Staphylococcus aureus has a significant effect on Austria Marcycline is highly sensitive


    In addition to omacycline, Genting Sunyao also introduced a new type of tetracycline antibiotic-eravacycline from Tetraphse Pharmaceuticals


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.